Amy Heath - Concepedia

Concepedia

Author

Amy Heath

Research Triangle Park Foundation

Also Known As

A. T. HEATH, A.T. Heath, Amy Heath, Amy T Heath, Amy T. Heath

27

Publications

1.5K

Citations

11

H-Index

7

Concepts

All Affiliations

Research Triangle Park Foundation GlaxoSmithKline (United States)Indivior (United States)University of California, Los Angeles GlaxoSmithKline (United Kingdom)

AH

About

Amy Heath is an author at Research Triangle Park Foundation specializing in medicine, immunology, and allergy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	492
2	Allergy	1	1	424
3	Gastroenterology	1	1	68
4	Immunology	1	1	424
5	Immunodeficiencies	1	1	424

Amy Heath

×

14

Publications

1.5K

Citations

11

H-Index

	Year	Citations
An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis Amal Assa’ad, Sandeep K. Gupta, Margaret H. Collins, Gastroenterology AllergyEsophageal Intraepithelial EosinophilsImmunodeficienciesMedicineImmunology	2011	424
A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome Michael Camilleri, William Y. Chey, Emeran A. Mayer, Archives of Internal Medicine	2001	304
Long-Term Safety and Efficacy of Alosetron in Women with Severe Diarrhea-Predominant Irritable Bowel Syndrome William D. Chey, William Y. Chey, Amy Heath, The American Journal of Gastroenterology	2004	146
Additional Investigations Fail to Alter The Diagnosis of Irritable Bowel Syndrome in Subjects Fulfilling The Rome Criteria Lynne Hamm, Susan C. Sorrells, Jacqueline P Harding, The American Journal of Gastroenterology	1999	125
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of 0.5 mg and 1 mg Alosetron in Women With Severe Diarrhea-predominant IBS Richard A. Krause, Vanessa Z. Ameen, Susan Gordon, The American Journal of Gastroenterology	2007	118
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus Daniel J. Wallace, Ellen M. Ginzler, Joan T. Merrill, Arthritis & Rheumatology	2019	100
Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension Ronald van Vollenhoven, Sandra Navarra, Roger A. Levy, Lara D. Veeken	2019	78
Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials Anthony Lembo, Kevin W. Olden, Vanessa Z. Ameen, Clinical Gastroenterology and Hepatology Food IntoleranceFunctional Gastrointestinal DisorderBowel UrgencyControlled TrialsGastroenterology	2004	68
Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients Laurence Moss, Marijke Hyke Algera, Robert L. Dobbins, PLoS ONE	2022	38
Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome JP Harding, Lynne Hamm, R. S. B. Ehsanullah, Alimentary Pharmacology & Therapeutics	1997	32

Page 1